Generic Medicine Info
Hypersensitivity. Treatment of rosacea, perioral dermatitis, acne vulgaris, perianal or genital pruritus; viral lesions of the skin (e.g. herpes simplex or zoster, varicella); bacterial or fungal infection of the skin, parasitic infections, skin symptoms relating to tuberculosis or syphilis, eruptions following vaccinations, burns, ulcerous wounds. Atrophy at treatment site. Primary infections of the scalp (scalp solution). Children <1 year (ointment, cream, scalp solution); <2 years (shampoo).
Special Precautions
Patient with history of local hypersensitivity to other corticosteroids. Children. Pregnancy and lactation. Patient Counselling Avoid contact with eyes, eyelids, face, nose, mouth, axillae, or groin. Do not use with occlusive dressing. Monitoring Parameters Monitor for HPA axis suppression with prolonged use through ACTH stimulation test, morning plasma cortisol test, and urinary free cortisol test; ocular changes.
Adverse Reactions
Significant: Hypothalamic-pituitary-adrenal (HPA) axis suppression or hypercortisolism particularly in younger children (high dose for prolonged treatment); Kaposi sarcoma (prolonged use); allergic contact dermatitis, local effects (e.g. folliculitis, skin atrophy, perioral dermatitis, telangiectasia, acneiform eruptions), skin infections; osteonecrosis (prolonged use); ocular effects (e.g. posterior subcapsular cataracts, glaucoma, central serous chorioretinopathy); systemic effects (e.g. manifestations of Cushing's syndrome, hyperglycaemia, glycosuria). Rarely, generalised pustular psoriasis (prolonged use in psoriasis). General disorders and administration site conditions: Application site reactions. Nervous system disorders: Headache. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, upper respiratory tract infection. Skin and subcutaneous tissue disorders: Pruritus, skin dryness, striae, local skin burning sensation, skin pain.
Drug Interactions
Increased systemic exposure with CYP3A4 inhibitors (e.g. itraconazole, ritonavir). May diminish the antineoplastic effect of aldesleukin.
CIMS Class
Psoriasis, Seborrhea & Ichthyosis Preparations / Topical Corticosteroids
ATC Classification
D07AD01 - clobetasol ; Belongs to the class of very potent (group IV) corticosteroids. Used in the treatment of dermatological diseases.
Disclaimer: This information is independently developed by CIMS based on clobetasol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in